NVO - Novo Nordisk A/S
| Previous Close | 48.28 |
| Open | 47.88 |
| Bid | 0.00 x 1800 |
| Ask | 0.00 x 800 |
| Day's Range | 47.58 - 48.17 |
| 52 Week Range | 41.23 - 52.83 |
| Volume | 2,178,743 |
| Avg. Volume | 1,440,723 |
| Market Cap | 114.202B |
| Beta (3Y Monthly) | 0.78 |
| PE Ratio (TTM) | 19.49 |
| EPS (TTM) | 2.46 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.25 (2.59%) |
| Ex-Dividend Date | 2019-03-22 |
| 1y Target Est | 53.90 |
- Zacks•7 days ago
Gilead-Galapagos Ink $5.1B Deal for Additional Compounds
Gilead (GILD) collaborates with Galapagos for additional compounds for $5.1 billion and ups its stake in the latter to 22%.
- Zacks•10 days ago
Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY
Glaxo (GSK) provides updates on HIV regimens. FDA accepts Merck (MRK) & Sanofi's (SNY) regulatory applications for review.
- MarketWatch•10 days ago
Sunnova Energy to offer 17.6 million shares in IPO, priced at $16 to $18 each
Sunnova Energy International Inc. set terms for its planned initial public offering, saying in a regulatory filing it plans to offer 17.6 million shares priced at $16 to $18 each. The Houston-based solar energy company would raise $316.8 million at the top of that range. Seven banks are underwriting the deal, led by BofA Merrill Lynch, JPMorgan and Goldman Sachs. Proceeds will be used to pay down debt and for general corporate purposes.
- Zacks•12 days ago
Court Ruling Topples Trump Order, No Price Display in TV Ads
The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.
- Zacks•13 days ago
Novo Nordisk Reports Encouraging Data From Hemophilia Studies
Novo Nordisk (NVO) reports data on Concizumab and Refixia for the treatment of hemophilia.
- Simply Wall St.•13 days ago
Would Novo Nordisk A/S (CPH:NOVO B) Be Valuable To Income Investors?
Dividend paying stocks like Novo Nordisk A/S (CPH:NOVO B) tend to be popular with investors, and for good reason...
- Investopedia•16 days ago
The Top 10 Biotechnology Companies (JNJ, ROG.VX)
Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.
- Market Realist•21 days ago
A Look at NVO’s Spending and Earnings in Fiscal 2019
In the first-quarter earnings investor presentation, Novo Nordisk (NVO) guided for YoY operating profit growth of 2% to 5%.
- Market Realist•21 days ago
How NVO’s Revenues Are Trending in Fiscal 2019
Novo Nordisk (NVO) has guided for YoY revenue growth of 2% to 5% at a constant exchange rate in fiscal 2019.
- Market Realist•21 days ago
What Analysts Recommend for GlaxoSmithKline and Novo Nordisk
GlaxoSmithKline (GSK) is up by 5.02%, and Novo Nordisk (NVO) is up by 10.51% in 2019 on a YTD basis.
- Market Exclusive•21 days ago
Market Morning: OPEC Cuts, Trump & Xi Ceasefire, Apple Goes to China, Deutsche Bank Hiring
OPEC Cuts Maintained, Putin and Bin Salman On Same Page Russia and Saudi Arabia agreed on an extension to the previous OPEC oil production cuts by 6 to 9 months. The meeting takes place today and tomorrow, July 1 and 2. The oil price environment since 2014 has pushed OPEC and Russia together somewhat, and […]The post Market Morning: OPEC Cuts, Trump & Xi Ceasefire, Apple Goes to China, Deutsche Bank Hiring appeared first on Market Exclusive.
- Insider Monkey•22 days ago
How Adobe Inc and Other Hedge Fund Favorites Performed in Q2
Insider Monkey tracks hedge funds, billionaires, and prominent value investors for a very simple reason: their consensus picks generally outperform the market. We aren’t the only research shop broadcasting this fact using a bullhorn. Here is what strategist Ben Snider said in Goldman Sachs’ periodic hedge fund report: “Despite the strong track record of popular […]
- Benzinga•23 days ago
The Week Ahead In Biotech: Pending Clinical Readouts In Focus
Biotech stocks headed south last week, reversing decent gains made in the previous week. Unfavorable FDA decisions, botched trials and weaker broader market sentiment all weighed down on the sector. Here ...
- Zacks•25 days ago
Lilly's Study on Higher Doses of Trulicity Meets Endpoint
Lilly's (LLY) phase III study evaluating higher doses of Trulicity meets primary and secondary efficacy endpoints.
- Zacks•26 days ago
Gilead Inks Deal With Carna Biosciences for Immuno-Oncology
Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology.
- Motley Fool•27 days ago
The 10 Biggest Biotech Stocks
Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.
- Zacks•last month
Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval
Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.
- Zacks•last month
Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod
Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.
- Zacks•last month
Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs
Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.
- Zacks•last month
NVS or NVO: Which Is the Better Value Stock Right Now?
NVS vs. NVO: Which Stock Is the Better Value Option?
- Zacks•last month
Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients
Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.
- Benzinga•last month
The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 17) ArQule, Inc. (NASDAQ: ARQL )( reported positive results ...
- MarketWatch•last month
Shares of cancer-therapy companies skyrocket after Pfizer acquisition news
Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion.
- MarketWatch•last month
FDA approves non-insulin Type 2 diabetes drug for kids, the first to hit market in 20 years
The U.S. Food and Drug Administration on Monday approved Novo Nordisk's Victoza, a liraglutide injection, for the treatment of young patients 10 years or older with Type 2 diabetes. Although Victoza has been FDA-approved to treat adults with Type 2 diabetes since 2010, it is the only non-insulin drug approved for children other than metformin, which was approved for pediatric use in 2000. "Victoza has now been shown to improve blood sugar control in pediatric patients with Type 2 diabetes. The expanded indication provides an additional treatment option at a time when an increasing number of children are being diagnosed with this disease," said Lisa Yanoff, acting director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research. Type 2 diabetes occurs when the pancreas is unable to make enough insulin to keep blood sugar at normal levels. It's the most common form of diabetes, normally occurring in patients 45 years or older. However, in the past two decades, its prevalence among younger patients has dramatically risen. More than 5,000 new cases of Type 2 diabetes are now diagnosed each year in the U.S. among people younger than age 20, according to the Centers for Disease and Control and Prevention. Shares of Novo Nordisk have gained 10.8% so far this year, while the SPDR S&P Pharmaceuticals ETF has gained 3%. The Dow Jones Industrial Average has gained 11.8% and the S&P 500 has gained 15.3%.
- Zacks•last month
Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
